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Abstract: 
Background and Aims:  
Veterans have higher prevalence of colorectal neoplasia than non-veterans; 
however, it is not known whether specific Veterans Affairs (VA) adenoma detection 
rate (ADR) benchmarks are required. We compared ADRs of a group of endoscopists 
for colonoscopies performed at a VA to their ADRs at a non-VA academic medical 
center. 
 
Methods: 
This was a retrospective review of screening colonoscopies performed by 
endoscopists who practice at the Indianapolis VA and Indiana University (IU). 
Patients were average-risk males aged 50 years or older. ADR, proximal adenoma 
detection rate, advanced adenoma detection rate, and adenomas per colonoscopy 
were compared between IU and the VA groups. 
 
Results: 
Six endoscopists performed screening colonoscopies at both locations during the 
study period (470 at IU vs 608 at the VA). The overall ADR was not significantly 
different between IU and the VA (58% vs 61%; p =0.21). Advanced neoplasia 
detection rate (13% vs 17%; p=0.46), proximal adenoma detection rate (46% vs 
47%; p=0.31), and adenoma per colonoscopy (1.59 vs 1.84; p=0.24) were not 
significantly different. There were no significant differences in cecal intubation rate 
(100% vs 99%; p=0.13) or withdrawal time  (10.9 vs 11.1 min; p=0.28). 
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In regression analysis, there was significant correlation between the attending-
specific ADRs at IU and the VA (p=0.041, r-square=0.69). 
 
Conclusions: 
In this study of average-risk males undergoing screening colonoscopies by the same 
group of endoscopists, the ADRs of VA and non-VA colonoscopies were not 
significantly different. This suggests that a VA-specific ADR target is not required for 
endoscopists with high ADR.  
 
 
Keywords: Colonoscopy, Adenoma Detection Rate, Veterans Affairs 
 
Introduction 
The adenoma detection rate (ADR), or the proportion of average-risk 
screening colonoscopies with at least one adenoma, is the primary colonoscopy 
quality indicator  (1). A higher endoscopist ADR indicates a higher quality 
examination and has been shown to be inversely associated with the risk of 
postcolonoscopy colorectal cancer (PCCRC) (2,3).  Current ADR targets 
recommended by the ASGE/ACG Task Force are categorized by gender, and are 20% 
in females and 30% in males 50 years or older (1), reflecting the higher prevalence 
of colorectal neoplasia in men. There are currently no recommendations for 
additional ADR target adjustments based on other characteristics of the screened 
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population which are known to influence adenoma prevalence, such as 
race/ethnicity, family history, and lifestyle factors such as smoking and obesity (4). 
The Veterans Affairs (VA) system is one of the largest integrated healthcare 
systems in the United States, and provides care to nearly 9 million veterans a year.  
Most veterans are male, older, and have a higher prevalence of lifestyle risk factors 
(such as smoking), which might explain the higher prevalence of colorectal 
neoplasia compared with non-veteran populations (5-9). It is not known whether 
the minimum benchmark ADRs, which were developed and validated in non-veteran 
populations, require revision for patients who receive their care in the VA system.  
Although the VA has recently recognized the importance of measuring colonoscopy 
quality via National Directive 1015, benchmarks for ADR have not been specified, 
although it is generally assumed that 30% would be used by default, given that most 
VA patients are male (10).  
The question of whether there should be a VA-specific ADR cannot be 
answered by comparing historical data between VA and non-VA settings, because 
such an approach does not take into account the operator-dependency of 
colonoscopy quality (11). Any comparison between the VA and other systems 
should compare the ADR of the same group of endoscopists working within and 
outside the VA. The structure of the endoscopy programs at our institution offers an 
opportunity to perform such a study. The Indianapolis VA is academically affiliated 
with, and completely integrated with the overall clinical operation at Indiana 
University.  All GI faculty with VA responsibilities have academic appointments with 
the university and practice at the VA and at other non-VA IU centers. The endoscopy 
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units have very similar infrastructure and resources, high commitment to quality, 
and use the same colonoscope models and bowel preparation options and grading.   
 We conducted this study to compare ADRs at the Indianapolis VA endoscopy 
unit to ADRs at the non-VA Indiana University (IU) endoscopy units for a group of 
endoscopists who practice at both locations. 
 
Methods: 
The study was approved by the institutional review board (IRB) at Indiana 
University and by the Research and development committee at the Roudebush 
Veterans Affairs Medical Center in Indianapolis, Indiana. 
 
Patient population 
This was a retrospective study which included average-risk screening 
colonoscopies performed between October 1, 2012 and September 30, 2015 at the 
Indianapolis VA medical center and at Indiana University (IU) by all 
gastroenterologists practicing at both institutions. 
Data sources used for the study were the Veterans Affairs Vista 
Computerized Patient Record System (CPRS) for VA patients’ information, Cerner 
(Cerner, Kansas City, Mo, USA) for IU patients’ information, and Provation 
(Provation Medical Inc, Minneapolis, Minn, USA) for colonoscopy reports.  
We included only colonoscopies performed on males who were ≥50 years old 
at time of colonoscopy and for an indication of average-risk screening for colorectal 
cancer (no more than one first-degree relative (FDR) with CRC diagnosed at age 
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older than 60 years). Colonoscopies performed on patients with FDR with CRC 
diagnosed at age younger than 60 years or those who had more than one FDR with 
CRC diagnosed at any age were excluded. Colonoscopies performed for any 
indication other than screening for CRC, such as postpolypectomy surveillance and 
diagnostic colonoscopies that included evaluation of positive fecal immunochemical 
tests were also excluded. “Re-screening” colonoscopies  (colonoscopies performed 
10 years after a negative baseline screening colonoscopy) were included in the 
study (12,13).  
 
Data Collection 
We identified all gastroenterologists who practiced at both locations during 
the study time frame. Then, their eligible screening colonoscopy reports during the 
study period at IU and at the VA were identified. For all included patients, 
demographic and clinical data were collected from the colonoscopy report and the 
electronic medical record. Data included location (VA or IU), procedure date, time of 
day (AM or PM), weekend or weekday, procedure performance by attending 
physician alone or by a fellow under attending physician supervision, patient 
demographic and physical characteristics (including age, sex, ethnicity, race, weight, 
height), tobacco use, alcohol use, aspirin and NSAIDs use, Charlson comorbidity 
score, family history of colon cancer or polyps, withdrawal time (for colonoscopies 
where no polypectomy was performed), first time or re-screening colonoscopy 
status, bowel preparation quality based on the Aronchick scale, cecal intubation, and 
location, shape, size in millimeters, and histology of each resected polyp.  
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Study endpoints 
Our primary comparison was between the ADR at the VA and the ADR at IU 
for all gastroenterologists who performed average-risk screening colonoscopies at 
both locations during the study period. 
Secondary comparisons between the 2 groups were performed for the advanced 
neoplasia detection rate, mean adenomas per colonoscopy, and serrated polyp 
detection rate.  
Advanced neoplasms were defined as advanced adenomas (1 cm, villous histology, 
high-grade dysplasia) and cancer. Serrated polyps included hyperplastic polyps and 
sessile serrated polyps. Proximal location was defined as proximal to splenic flexure. 
 
Statistical Analysis 
The VA and IU groups were compared for differences in patient 
characteristics using 2-sample t-tests and chi-square tests for continuous and 
categorical variables, respectively. Generalized estimating equation (GEE) models 
applied to logistic regression and negative binomial regression were used to 
compare the groups for differences in the presence and number of adenomas, 
proximal adenomas, serrated polyps, proximal serrated polyps, any polyps, 
advanced neoplasms, and cancer, respectively. GEE models applied normally 
distributed data were used to compare the groups for differences in withdrawal 
time after a natural logarithm transformation of the withdrawal times. GEE models 
were used to account for clustering of patients within attending doctors. The 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
following were included in the GEE models as covariates: age, body mass index 
(BMI), Charlson score, time of day (AM or PM), weekend, fellow participation, race 
(white or non-white), smoker (current/prior or not), alcohol use, aspirin  or NSAID 
use, and rescreening . Linear regression analysis was explored for examining the 
association between attending-specific ADRs at IU and the VA. Analyses were 
performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC). A 5% significance 
level was used for all tests. 
 
Results: 
We identified 6 gastroenterologists who performed screening colonoscopies 
in average-risk patients between October 1, 2012 and September 30, 2015 at IU and 
the VA. A total of 470 IU and 608 VA colonoscopies were included in the analysis. 
Patients’ characteristics are presented in table 1. Patients at the VA were 
older, had higher Charlson comorbidity scores, and higher BMI. They were also 
more likely to be non-white, be smokers, use aspirin, use NSAIDs, have FDR with 
CRC at age older than 60 years, and their colonoscopies to be done in the afternoon, 
on the weekend, by a fellow under direct supervision, and have a “re-screening” 
indication compared with IU patients. They were less likely to drink alcohol. . 
The overall ADR was not significantly different between the 2 groups  (58% 
at IU vs 61% at the VA; p-value=0.21 (table 2)). In addition, detection rates of 
proximal adenomas, advanced neoplasms, cancers, serrated polyps or any polyps 
were not significantly different between the 2 groups (table 2). 
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Cecal intubation rates were similar (100% at IU vs 99% at the VA  (p=0.13)). Bowel 
preparation quality was graded as excellent, good, or adequate in 94% of IU 
colonoscopies, compared with 89% of VA ones (p=0.007). Withdrawal times (WT) 
for colonoscopies without polypectomies were not significantly different (mean WT 
of 10.9 minutes at IU and 11.1 minutes at the VA, p-value 0.28 (table 3)). 
The number of polyps per colonoscopy was significantly higher at the VA, but 
the numbers of adenomas per colonoscopy (APC), proximal adenomas, serrated 
polyps, proximal serrated polyps, and advanced neoplasms per colonoscopy were 
not significantly different between IU and the VA (table 2).  
Outcomes of individual endoscopists at the VA and IU are represented in 
table 4.  Multivariable analysis comparing ADRs at IU versus VA for each of the 
gastroenterologists, revealed a significant correlation between the attending-
specific ADRs at IU and the VA (p=0.041, r-square=0.69) (figure 1). 
 
 
Discussion: 
This study showed that there was no significant difference between the ADR 
of colonoscopies performed by the same group of endoscopists in average-risk male 
veterans compared with average-risk male non-veterans. There was also no 
significant difference in advanced neoplasia detection rate or adenoma per 
colonoscopy detection rate between the 2 patient populations. These findings argue 
against setting a separate ADR benchmark for colonoscopies performed at the VA.  
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To our knowledge, this is the first study that compares ADR for the same 
group of endoscopists in veteran and non-veteran populations. Several studies have 
reported ADRs at VA institutions (5,8,9) and non-VA institutions (2,3,11, 14); 
however, comparisons of ADRs between the 2 settings have been limited by the 
inability to control for operator variability. The structure of our endoscopy 
programs at IU and the VA allowed us to overcome this limitation, as we were able 
to compare the ADRs of several endoscopists who performed colonoscopy at the VA 
and non-VA IU endoscopy units during the same time frame.  Our study design and 
setting also allowed us to control other variables that could affect yield for 
neoplasia, including the use of the same high-definition colonoscopes and bowel 
preparation strategies.   
Although overall ADR was not significantly different between the 2 groups, 
we did note that VA ADR was significantly higher for 2 endoscopists whose IU ADR 
was <40%. Thus it is possible that our observations depend on individual ADR, 
although additional study in a larger sample of endoscopists would be required to 
prove it.    
Our study has potential limitations. First, the 2 groups were matched by 
endoscopist and time period; however, patients did not have similar baseline CRC 
risk factors. Veterans were older, had higher comorbidity burden, higher BMI, 
higher prevalence of smokers, but also higher prevalence of aspirin and NSAID use 
which would be expected to be associated with lower risk of colorectal neoplasia. 
Second, our study included only males. Based on previous studies from our VA that 
included females, we had expected 6% to 9% of our patients to be female (9). This 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
small proportion was going to significantly limit our ability to compare female VA to 
female IU patients; hence our decision to limit the study to males. A third limitation 
is the relatively small number of endoscopists and colonoscopies performed during 
the study time period. Finally, our endoscopists had individual ADRs at the highest 
end of the spectrum of reported ADRs, far higher than the ACG-ASGE ADR target of 
30% for males (1). This could have limited our ability to detect significant 
differences between VA and non-VA settings. It is not known whether our findings 
would differ in non-academic settings, or for endoscopists with lower ADRs.  
In conclusion, this study of average-risk males undergoing screening 
colonoscopies by the same group of endoscopists did not show a significant 
difference between ADR at the VA compared with ADR at a non-VA academic center. 
This suggests that a VA-specific ADR target is not required. Additional study is 
warranted in settings where endoscopists have a wider range of ADR variability.    
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Table 1: Patient characteristics 
  IU (n=470) VA (n=608) P value 
Age  58.07 (7.62) 60.25 (6.62) <.001 
Weight (kg)  91.56 (16.92) 96.06 (19.88) <.001 
BMI  28.86 (5.42) 30.50 (6.12) <.001 
Charlson score  0.94 (1.28) 1.47 (1.31) <.001 
Time of day PM 32 (7%) 137 (23%) <.001 
 AM 438 (93%) 471 (77%)  
Weekend Yes 1 (<1%) 213 (35%) <.001 
 No 469 (100%) 395 (65%)  
Fellow Yes 43 (9%) 150 (25%) <.001 
 No 427 (91%) 458 (75%)  
Ethnicity No answer 15 (3%) 29 (5%) 0.010 
 Hispanic 8 (2%) 1 (<1%)  
 Not Hispanic 447 (95%) 578 (95%)  
Race No answer 15 (3%) 28 (5%) <.001 
 Other 1 (<1%) 0 (0%)  
 
Native Hawaiian/Pacific 
islander 2 (<1%) 1 (<1%)  
 Asian 12 (3%) 1 (<1%)  
 
American Indian/Alaska 
native 2 (<1%) 2 (<1%)  
 Black/African-American 39 (8%) 123 (20%)  
 White 399 (85%) 453 (75%)  
Smoker No info 84 (18%) 121 (20%) <.001 
 Previous 55 (12%) 34 (6%)  
 Yes 60 (13%) 223 (37%)  
 No 271 (58%) 230 (38%)  
Alcohol No info 96 (20%) 22 (4%) <.001 
 Yes 201 (43%) 183 (30%)  
 No 173 (37%) 403 (66%)  
Aspirin Yes 180 (38%) 301 (50%) <.001 
 No 290 (62%) 307 (50%)  
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NSAIDs Yes 60 (13%) 109 (18%) 0.021 
 No 410 (87%) 499 (82%)  
FDR cancer Yes 6 (1%) 21 (3%) 0.023 
 No 464 (99%) 587 (97%)  
FDR polyps Don’t know 0 (0%) 20 (3%) <.001 
 Yes 1 (<1%) 7 (1%)  
 No 469 (100%) 581 (96%)  
Rescreening Yes 21 (4%) 58 (10%) 0.002 
 No 449 (96%) 550 (90%)  
Continuous variables (age, weight, BMI, Charlson score) are presented as Mean (SD). 
Categorical variables are presented as n(%). 
 
 
 
 
 
 
Table 2: Colonoscopy outcomes  
  IU (n=470) VA (n=608) P value 
Any adenoma (ADR)  271 (58%) 368 (61%) 0.214 
Any proximal adenoma  218 (46%) 284 (47%) 0.310 
Any serrated polyp  192 (41%) 196 (32%) 0.337 
Any proximal serrated polyp  97 (21%) 81 (13%) 0.598 
Any polyp  359 (76%) 474 (78%) 0.192 
Any advanced neoplasm  62 (13%) 103 (17%) 0.457 
Any cancer  6 (1%) 7 (1%) 0.918 
Adenomas per colonoscopy  1.59 (2.71) 1.84 (2.72) 0.242 
Proximal adenomas per 
colonoscopy 
 
1.13 (2.19) 1.20 (2.02) 0.221 
Serrated polyps per 
colonoscopy 
 
0.82 (1.37) 0.78 (1.77) 0.419 
Proximal serrated polyps per 
colonoscopy 
 
0.37 (0.88) 0.23 (0.74) 0.502 
Polyps per colonoscopy  2.53 (3.12) 2.98 (3.54) 0.007 
Advanced neoplasms per 
colonoscopy 
 
0.24 (0.90) 0.26 (0.71) 0.463 
Cancers per colonoscopy  0.03 (0.25) 0.01 (0.16) --- 
Cecal Intubation  468 (100%) 600 (99%) 0.131 
Bowel Prep Poor/Inadequate 4 (1%) 16 (3%) 0.007 
 Fair 22 (5%) 46 (8%)  
 Excellent/Good/Adequate 443 (94%) 516 (89%)  
Categorical outcomes are presented as n (%). Continuous outcomes are presented 
as mean (SD). The p-values are adjusted for covariates described in the text. 
 
 
 
 
Table 3: Withdrawal times for colonoscopies without any polyps 
   IU  VA  
 Attending N Mean (SD) N Mean (SD) P value 
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Withdrawal time (minutes) All 107 10.9 (4.0) 128 11.1 (5.5) 0.277 
 A 13 11.6 (2.7) 41 15.3 (6.1) 0.080 
 B 53 12.1 (4.5) 7 8.8 (1.9) 0.221 
 C 14 10.0 (3.5) 14 11.6 (6.2) 0.256 
 D 18 8.2 (2.4) 16 6.7 (1.1) 0.454 
 E 2 11.6 (1.9) 18 7.6 (1.8) 0.118 
 F 7 8.5 (1.1) 32 10.3 (3.9) 0.345 
(4 patients at IU and 6 patients at the VA did not have polyps but did not have 
recorded withdrawal times). Total number of patients without polyps is 111 and 
134, respectively. 
 
 
 
 
 
Table 4: ADR, Advanced neoplasia detection rate and APC for each individual 
endoscopist 
Attending Total Procedures ADR Advanced 
neoplasms 
detection rate 
Adenoma per 
colonoscopy 
IU VA IU VA IU VA IU VA 
A 41 268 49% 68% 12% 17% 1.34 
(2.20) 
1.96 
(2.48) 
B 274 46 62% 65% 14% 18% 1.80 
(2.97) 
2.18 
(3.83) 
C 69 60 69% 60% 10% 10% 1.65 
(1.87) 
1.45 
(2.08) 
D 38 39 29% 40% 10% 17% 0.51 
(1.03) 
1.10 
(2.39) 
E 6 66 43% 48% 14% 14% 0.43 
(0.53) 
1.45 
(2.39) 
F 19 118 37% 57% 16% 20% 1.47 
(4.31) 
2.11 
(3.18) 
 
 
 
 
 
 
 
Figure 1: ADRs of individual gastroenterologists at IU and the VA showing a positive 
relationship (p=0.041; r-square=0.69). 
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